Table 1.
Patient characteristics
| Characteristic | Patients, No. (%) (N = 684) |
|---|---|
| Sex | |
| Female | 270 (39.5) |
| Male | 414 (60.5) |
| Age, median (range), y | 61 (19-88) |
| Site treated | |
| Central nervous system | 88 (12.9) |
| Head and neck | 85 (12.4) |
| Lung | 116 (17) |
| Abdomen | 274 (40.1) |
| Esophagus | 83 (12.1) |
| Liver | 73 (10.7) |
| Pancreas | 101 (14.8) |
| Other abdomen | 17 (2.5) |
| Pelvis | 121 (17.7) |
| Cervix/endometrium | 35 (5.1) |
| Rectum | 64 (9.4) |
| Anus | 22 (3.2) |
| Radiation regimen | |
| Dose per fraction, median (range), Gy | 2.0 (1.33-20.0) |
| Total dose, median (range), Gy | 50.0 (30.0-70.0) |
| Chemotherapy regimen | |
| None | 82 (12.0) |
| Gemcitabine alone | 71 (10.4) |
| 5-FU or capecitabine alone | 100 (14.6) |
| 5-FU/Mitomycin C | 21 (3.1) |
| Platinum (cis- or carboplatin) | 94 (13.7) |
| Platinum doublet | 160 (23.4) |
| +paclitaxel | 85 (12.4) |
| +5-FU | 30 (4.4) |
| +other | 45 (6.6) |
| Temozolomide | 88 (12.9) |
| Biologic | 10 (1.5) |
| Other/unknown | 58 (8.5) |
Abbreviation: 5-FU = 5-fluorouracil.
Data are presented as the number (percentage) of patients unless otherwise indicated.